Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo

BMC Complementary and Alternative Medicine

Research Article

Jinhee Kim¹  Jin-Mu Yi¹  Se-Mi Oh¹  Dal-Seok Oh¹  Ok-Sun Bang¹  Jun Lee¹  Jong-Shik Park¹  No Soo Kim¹ 

[1] KM-Based Herbal Drug Research Group, Herbal Medicine Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, 305-811, Yuseong-gu, Daejeon, Republic of Korea;

关键词: Gleditsia sinensis;    Antiangiogenesis;    Anticancer;    Gene expression;    Medicinal herb;   

DOI  :  10.1186/1472-6882-12-243

 received in 2012-07-30, accepted in 2012-11-29,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundGleditsia sinensis thorns have been widely used in traditional Korean medicine for the treatment of several diseases, including obesity, thrombosis, and tumor-related diseases. The aim of the study is to determine the antiangiogenic effect of Gleditsia sinensis thorns in vitro and in vivo in a bid to evaluate its potential as an anticancer drug.MethodsEthanol extract of Gleditsia sinensis thorns (EEGS) were prepared and used for in vitro and in vivo assays. In vitro antiangiogenic effect of EEGS was determined in HUVEC primary cells by cell migration and tube formation assays. In vivo antiangiogenic effect of EEGS was determined by measuring vessel formation and vascular endothelial cells migrating into the implanted matrigels in nude mice. The angiogenesis-related proteins of which expression levels were altered by EEGS were identified by proteomic analysis.ResultsEEGS exerted a dose-dependent antiproliferative effect on HUVEC cells without significant cytotoxicity. Angiogenic properties, such as cell migration and tube formation, were significantly inhibited by EEGS in a dose-dependent manner. New vessel formation was also suppressed by EEGS, as determined by the directed in vivo angiogenesis assays in nude mice. EEGS reduced the expression of proangiogenic proteins, endothelin 1 and matrix metallopeptidase 2, in HUVEC cells.ConclusionsOur findings suggest that EEGS can inhibit angiogenesis by down-regulating proangiogenic proteins, and therefore it should be considered as a potential anticancer drug targeting tumor-derived angiogenesis.

【 授权许可】

Unknown   
© Yi et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.